Lilly and FDA head toward decision on whether retatrutide is a biologic
A fight over how retatrutide is classified could shape when lower-cost copies of the experimental obesity drug reach the US market [1].
Eli Lilly and the FDA are still fighting over whether retatrutide — the company's experimental obesity drug — counts as a biologic, a decision that will shape how Lilly files for approval and how many years it keeps competitors off the market [1].
Lilly sued the FDA in September 2024 after the agency determined retatrutide is neither a protein nor a biological product, which made it ineligible for a biologics license application, or BLA [1]. Under that ruling, Lilly would have to file a new drug application, or NDA, instead. The two pathways carry different requirements for evidence and different exclusivity: a BLA gives 12 years of market exclusivity, while an NDA gives five [1]. BioSpace reported the gap could be worth tens of billions of dollars to Lilly [1].
The disagreement comes down to amino acids. The FDA defines a protein as any alpha amino acid polymer with 40 or more amino acids. Lilly's complaint says retatrutide has 41 amino acids [1]. The FDA agreed the drug is an alpha amino acid polymer and has a sequence of amino acids, but said it does not have 40 or more alpha amino acids, and classified it as a drug [1].
"But 41 is plainly 'greater than 40,'" Lilly argued, adding that counting only alpha amino acids conflicts with the agency's own prior findings [1]. The FDA defended its approach during oral arguments in September 2025, saying its regulatory text specifically names alpha amino acids and that history and precedent support that reading [1]. Lilly has also argued retatrutide is "analogous to" a protein. A lawyer for the agency told the court that "Eli Lilly points to no source at all that explicitly says what it wishes" [1].
The courts have given a mixed result so far: a decision vacated the FDA's biologics designation, but sent the question of whether retatrutide is "analogous to a protein" back to the agency. Lilly has appealed [1].
On the company's August 5, 2026 earnings call, CEO Dave Ricks said Lilly believes retatrutide qualifies as a biologic "both in terms of [the] amino acid count rule as well as analogous to a protein, so that's our position" [1]. An analyst noted that Dan Skovronsky, Lilly's chief scientific and product officer, said the company will pursue a BLA [1]. Ricks described the matter as active litigation but added, "we would hope to come to a conclusion with the FDA to support a BLA application" [1].
Lilly now plans to file retatrutide for approval in the first quarter of 2027, later than the filing previously expected this year [1]. In the Phase 3 TRIUMPH-2 and TRIUMPH-3 trials, weight loss topped 20% at 80 weeks [1]. Ricks said the company has what it needs to submit for global registrations in obesity, obstructive sleep apnea and knee osteoarthritis pain, while it continues to collect some manufacturing-related data [1]. If the FDA rejects a BLA, the drug could be delayed [1].
The filing question sits inside a larger business picture. Lilly reported $23 billion in second-quarter revenue; shares rose nearly 5% to $1,170 in premarket trading, and the company's market cap was $1.02 trillion as of the end of July [1]. Ricks compared retatrutide with Novo Nordisk's semaglutide franchise and Lilly's own tirzepatide and oral orforglipron, sold as Foundayo, saying, "We have a pretty large lead over any competitors with a triple-acting medicine" [1].
Why it matters for patients
Retatrutide is not approved and is not available by prescription. This dispute is about how it would be regulated if it is approved, not about whether it works or is safe [1]. The classification decides how long Lilly would hold exclusive rights. Twelve years under a BLA versus five under an NDA affects when lower-cost copies — biosimilars in the biologic pathway, generics in the drug pathway — could reach the market, and how much competition shapes price [1]. It also changes what evidence the FDA would require before approval [1]. Separately, a fight over a few amino acids could set a pattern for other incretin drugs in development [1].
What happens next
Lilly's appeal of the court decision is pending, and no ruling date has been reported [1]. The company has said it aims to file retatrutide in the first quarter of 2027 and will update investors on the filing status as the litigation progresses, and Ricks said Lilly is in communication with the FDA [1].
Sources
Semaglutides.org provides information only, not medical advice. Talk to a licensed provider about your own care before making changes. Some telehealth links are affiliate links and are labeled where they appear.